The story behind Allergan’s bold decision to formalize its social contract with patients told to our Chief Editor by Brent Saunders, Allergan’s chairman, president, and CEO.
At this year’s BIO International Convention in San Diego (June 19 – 22), I moderated a session, Navigating A Clear Path To Public-Private Partnerships, and we talked about the good, the bad, and the ugly of P3s. After a brief introduction, the first question was posed, resulting in the following edited dialogue.
Can a biopharma company have a soul? If so, the soul should be one that endures. “The biology is the soul of our company,” says Robert Blum, president and CEO of Cytokinetics. “We have pioneered an area of biology — muscle activation — proven to offer a compelling pharmacology.
Sometimes it pays to go against the grain. In 2013 Life Science Leader published an article describing the efforts of Dr. Ray Takigiku to establish Bexion Pharmaceuticals, a startup biotechnology firm, located in Covington, KY.
It’s been a little over a year since Sanat Chattopadhyay was named president of Merck Manufacturing Division (MMD), and this month he gives an exclusive interview on the status of the division’s transformational turnaround.
As former chairman and CEO of Pfizer, Jeffrey Kindler dealt with the frustrating conundrum of ballooning R&D budgets tracking alongside plunging R&D productivity. Now as he leads this chronic pain biopharma startup, he has a whole new set of challenges.
“You don’t have time to invest in basic research and wait 10 years. You have to go find individuals and companies doing exciting research, engage them, and progress those new technologies through collaborations and funding,” explains Takeda’s Vincent Ling.
Cynthia Schwalm, president, North American commercial operations for Ipsen, gives the backstory of what happened when this company decided to change its approach to the U.S. market.
To take the pulse of the biopharma industry, Life Science Leader tracked down four CEOs age 40 and under. These are the people at the forefront of innovation — something that is no easy task in a heavily regulated, patient-centered industry. Biotech is not tech. Heading up a company that is developing a pharmaceutical is a lot more challenging and riskier than starting one in your garage that is developing the next mobile phone app.
Astellas has placed a big emphasis on oncology this year, pointing to its many assets, particularly in targeted therapies that are later stage, but also focusing through partnerships on immuno-oncology (IO). A conversation with Drs. Steven Benner, head of oncology, and Peter Sandor, head of oncology marketing strategy, follows.
Find out what life is like after retiring from a pharma CEO role. These 6 leaders speak — unrestrained by corporate lawyers and PR teams — about the current state of the industry.
More thoughts and comments from cancer immunotherapy experts augment our 2017 immuno-oncology update.
The story of how Juan Ramón Alaix was groomed for his CEO role and how Zoetis turned into the world’s largest publicly traded animal health company.
After the worldwide success of statins, no one expected the epic failure of a class of drugs designed by the biggest names in Big Pharma to double the reduction in cardiac risk seen with statins alone. Statins lowered LDL, the bad cholesterol. The new drugs, called cholesteryl ester transfer protein (CETP) inhibitors, would raise HDL, the good cholesterol. Taken together, the drugs would reduce risk of cardiovascular events by up to 80 percent — or at least that was the idea.